Finally, we used two CDK4/6 inhibitors, LY2835219 (Abemaciclib) and PD0332991 (Palbociclib), both of which are used in breast cancer patients, to see whether inhibition of CDK4/6 would reproduce the effects of calcium/ionomycin on TFEB activity. This evidence concerns the gene TFEB and breast cancer.